Drug Combination Details
| General Information of the Combination (ID: C29751) | |||||
|---|---|---|---|---|---|
| Name | Apigenin NP Info | + | HA14-1 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Adrenocortical carcinoma
[ICD-11: 2D11]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CAPN1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Ratio of Bax to Bcl-2 | ||||
| Up-regulation | Cytochrome c release | |||||
| In-vitro Model | SK-N-DZ | CVCL_1701 | Neuroblastoma | Homo sapiens | ||
| SH-SY5Y | CVCL_0019 | Neuroblastoma | Homo sapiens | |||
| IMR-32 | CVCL_0346 | Neuroblastoma | Homo sapiens | |||
| Experimental
Result(s) |
Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways. | |||||
